NCT00006363 - Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

720

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

June 30, 2005

Conditions

Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Childhood Acute Basophilic LeukemiaChildhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic Syndromesde Novo Myelodysplastic SyndromesUntreated Adult Acute Myeloid LeukemiaUntreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions

DRUG

cytarabine

Given IV

DRUG

daunorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

valspodar

Given IV

BIOLOGICAL

filgrastim

Given SC

DRUG

busulfan

Given orally

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous PBSCT

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous PBSCT

BIOLOGICAL

aldesleukin

Given SC

OTHER

clinical observation

Undergo clinical observation

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH